ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive: In agreement with our findings, in a study involving 82 CML patients, Seong et al. [19] reported a non-significant trend between the ABCG2 c.421A allele and higher imatinib Ctrough.